Terms ending in 2031
Every in-force patent on 3-D Matrix, Ltd.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,337,012 | Method and Composition for the Treatment, Prevention, and Diagnosis of Cancer Containing or Derived from Cancer Stem Cells In force · High confidence | National Cancer Center | In force | High confidence | |
| US 10,576,123 | Tissue Occluding Agent Comprising an Ieikieikieiki Peptide In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | |
| US 9,133,484 | Transfection Agent In force · High confidence | 3-D Matrix, Ltd. and Nippon Medical School Foundation | In force | High confidence | |
| US 10,596,225 | Tissue Occluding Agent Comprising An IEIKIEIKIEIKI Peptide In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by 3-D Matrix, Ltd..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.